Intervention

Chemotherapy drug

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 10 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials10
Recruiting3
Common conditions23
Lead sponsors shown10
Advertisement

Clinical trials

10 shown
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung CancerNCT05798845 · 2025-02-20
RECRUITING
Clinical Observational Studies:Integrative TCM and Western Medicine for Breast CancerNCT07096180 · 2024-01-01
RECRUITING
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationNCT05315700 · 2022-03-10
RECRUITING
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsNCT05787613 · 2023-07-10
ACTIVE_NOT_RECRUITING
CIETAI and Sequential Radiotherapy in Squamous Lung CancerNCT05892237 · 2023-07-01
UNKNOWN
Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer PatientsNCT05755581 · 2023-04-01
UNKNOWN
Olaparib Maintenance Therapy in Metastatic Breast CancerNCT05629429 · 2023-02-07
UNKNOWN
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung CancerNCT05573373 · 2022-12-20
UNKNOWN
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.NCT06326086 · 2022-08-01
UNKNOWN
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesNCT05081609 · 2022-01-11
ACTIVE_NOT_RECRUITING

Common conditions

Carcinoma, Non-Small-Cell Lung22L+ Cervical Cancer1Advanced Lung Cancer1Advanced Solid Tumor1Breast Cancer1EGF-R Positive Non-Small Cell Lung Cancer1Female Breast Cancer1Locally Advanced Solid Tumor1Metastatic Breast Cancer1Metastatic Solid Tumor1Neoadjuvant Melanoma1Neoadjuvant Non-Small Cell Lung Cancer1NSCLC1NSCLC Stage IV1Platinum-resistant Ovarian Cancer1Post Anti-PD-(L)1 Non-Small Cell Lung Cancer1Post Anti-PD-(L)1 Small Cell Lung Cancer1Post Anti-PD-1 Melanoma1Sarcopenia1Second or Third Line (2L/3L) Cervical Cancer1Solid Tumors1Third Line or Later (3L+) HER2+ Breast Cancer1Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)1

Trial status mix

UNKNOWN5
RECRUITING3
ACTIVE_NOT_RECRUITING2

Phase mix

PHASE26
PHASE14
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.